REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
REGENXBIO Inc. presented at the RBC Capital Markets Global Healthcare Conference 2026. The company's CEO discussed the importance of waiting for new FDA leadership before submitting their data set. This approach aims to enhance the chances of regulatory approval amidst ongoing debates in the investment community.
- ▪REGENXBIO Inc. participated in the RBC Capital Markets Global Healthcare Conference on May 20, 2026.
- ▪CEO Curran Simpson emphasized the strategic decision to wait for new FDA leadership before submitting their data set.
- ▪The investment community is currently debating the implications of this waiting period on regulatory approval.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908117-regenxbio-inc-rgnx-presents-at-rbc-capital-markets-global-healthcare-conference-2026"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
